KIR3DL1-based inhibitory CAR NK cell therapy alleviates on-target, off-tumor toxicity with retention of antitumor effects
Background Chimeric antigen receptor (CAR) T cell therapy has significantly improved outcomes in hematologic malignancies. However, its translation to solid tumors is hampered by on-target, off-tumor toxicity (OTOT) and antigen escape. These obstacles underscore the need for novel strategies that enhance antitumor efficacy while limiting OTOT. Methods We designed a NOT logic-gated CAR natural killer (NK) cell architecture that targets B7H3, a tumor-associated antigen, and endomucin (EMCN), an antigen serving as a safety marker in normal tissues. These dual CAR NK cells selectively targeted and eliminated B7H3-high tumor cells, whereas their activation was suppressed upon encountering normal cell models co-expressing B7H3 and EMCN. A panel of inhibitory intracellular domains derived from T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), killer cell immunoglobulin-like receptors 2DL1 (KIR2DL1) and 3DL1 (KIR3DL1), and sialic acid-binding immunoglobulin-like lectins 7 and 9 (Siglec-7/9) was screened to identify the optimal module for the EMCN-specific CAR NK cells. Results The dual CAR NK cells demonstrated precise tumor selectivity and markedly reduced OTOT relative to conventional B7H3-targeted CAR NK cells. The KIR3DL1 intracellular domain proved to be the most effective, robustly suppressing cytotoxicity upon recognition of EMCN on B7H3 + engineered SKOV3-EMCN cells and thereby conferring potent protection. Conclusion This KIR3DL1-based inhibitory dual CAR NK cell strategy, which exploits endogenous NK inhibitory signaling, enhances safety and presents a promising advance in CAR-based immunotherapy for solid tumors. Future studies should focus on optimizing this platform and evaluating its clinical potential.
Authors
- 唐文静
- Shanshan Yu
- Yong Liang
- Minghui Tong
- Lei Zhou
- Taotao Cai
Institutions
- Xuzhou Medical College (CN)
- Second People’s Hospital of Huai’an (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fimmu.2026.1960842
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00